Travere Therapeutics (TVTX) Earnings Date & Reports

Key Takeaways

• Travere Therapeutics reported a third quarter 2026 net loss of $0.55 per share, well below the consensus estimate of $0.02, driven by a $113.1 million in-process research and development (IPR&D) charge tied to its civorebrutinib licensing agreement with Everest Medicines.
• Total revenue reached $224.56 million, exceeding the $195.68 million consensus estimate and rising 98% year over year from $113.2 million.
• FILSPARI U.S. net product sales climbed to $200.2 million, up 120% year over year, supported by 1,932 new patient start forms across two indications.
• The company ended the quarter with $471.8 million in cash, cash equivalents, and marketable securities.
• Travere continues enrolling its Phase 3 HARMONY Study of pegtibatinase, with topline results expected in the second half of 2027.
• Get more context on the ticker's Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• For additional market insights, explore Trending AI Robots to see how AI-driven strategies are interpreting current conditions.

Earnings Context and Why It Matters

Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with FILSPARI (sparsentan) now commercialized for two indications: IgA nephropathy (IgAN, an immune-related kidney disease) and focal segmental glomerulosclerosis (FSGS, a scarring condition of the kidney's filtering units). This quarter mattered because it tested whether FILSPARI's commercial momentum could extend beyond its initial IgAN launch into the newer FSGS indication. Investors were watching for sustained prescription growth, payer access, and progress toward management's longer-term ambition of $3 billion in FILSPARI sales by 2033, while also assessing the financial impact of a major pipeline-licensing decision around civorebrutinib.

Reported Results

For the third quarter of 2026, Travere reported a net loss of $0.55 per share, missing the consensus estimate of $0.02 per share. The shortfall was primarily driven by a $113.1 million in-process research and development (IPR&D) expense recorded in connection with the company's exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib, an investigational therapy being explored for immune-mediated kidney diseases.

Revenue was a bright spot. Total revenue came in at $224.56 million, above the $195.68 million consensus and up 98% from $113.2 million in the prior-year quarter. U.S. net product sales of FILSPARI totaled $200.2 million, representing 120% year-over-year growth. The company received 1,932 new patient start forms during the quarter across both IgAN and FSGS.

Research and development (R&D) expenses increased to $70.3 million from $51.9 million a year earlier, largely reflecting advancement of the Phase 3 HARMONY Study and manufacturing for pegtibatinase. Selling, general, and administrative (SG&A) expenses rose to $98.4 million from $71.0 million, driven by commercial investments supporting the FSGS launch. The company reported cash and marketable securities of $471.8 million as of September 30, 2026.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market more efficiently. It lets users scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, volatility, and performance metrics. By combining fundamental data with AI-driven signals, the screener helps surface trade ideas, trending stocks, breakout candidates, and broader market opportunities that might be missed through manual screening. For investors tracking names like Travere Therapeutics, it offers a structured way to compare opportunities across the biotech sector and beyond.

Market Reaction and Investor Sentiment

Travere shares fell roughly 4.8% in after-hours trading following the report. The decline reflected the headline earnings miss, even though the shortfall stemmed from a large, largely one-time IPR&D charge rather than operational weakness. Analysts had set modest profitability expectations of $0.02 per share, so the $0.55 loss stood out sharply against that benchmark.

Beneath the accounting noise, investors appeared to weigh the strength of FILSPARI's commercial trajectory. The revenue beat and triple-digit product-sales growth underscored robust underlying demand, but the stock's reaction suggests the market focused on the bottom-line miss and the optics of an enlarged quarterly loss. The pending CEO transition and the forward-looking implication of inventory timing in specialty pharmacy channels also factored into near-term sentiment.

Forward Outlook and Key Factors to Monitor

Looking ahead, several factors will shape investor attention. First is FILSPARI's prescription momentum. Management noted that specialty pharmacy partners increased inventory above historical levels during the quarter, contributing roughly $8 million to net sales. The company expects fourth quarter net sales to be reduced by a similar amount as pharmacies dispense existing stock, making sequential sales comparisons a key figure to watch.

The FSGS launch remains an important catalyst. With most payers having updated coverage policies and roughly two-thirds of FSGS prescribers having treated only one patient so far, the pace of prescriber deepening will signal whether the newer indication can broaden the revenue base over time.

Beyond the commercial business, investors will monitor the Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria, with topline results expected in the second half of 2027. The planned year-end submission of a U.S. Investigational New Drug (IND) application for civorebrutinib also represents a near-term regulatory milestone.

Finally, the leadership transition to incoming CEO Bradley L. Campbell effective December 1, 2026, adds an element of strategic continuity to watch. While the company reiterated its long-term FILSPARI sales ambition of $3 billion by 2033, near-term performance will likely hinge on durable demand conversion and disciplined operating-expense management.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations